clinical trial · NCT07276386
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 18
Metastatic Uveal MelanomaMelphalan/HDS (Percutaneous Hepatic Perfusion)Tebentafusp
brief summary
This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances antigen release and immunomodulation, potentially sensitizing tumors to tebentafusp in HLA-A\*02:01-positive patients.
started
Dec 31, 2025
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Mar 31, 2026
official title
Phase 2 Sequential Treatment With Melphalan/HDS Via Percutaneous Hepatic Perfusion Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol